CFDE Data Portal | Search PRIM2BP

	Label	Description
	PRIM2BP Gene (Entity type)	ENSG00000283453 - primase 2B, pseudogene
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 3 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Testis 20-29 vs 60-69 Down Gene Set (Entity type)	A Gene Set from GTEx
	GSE119978 GSE180930 cisplatin 0 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

PRIM2BP

ENSG00000283453 - primase 2B, pseudogene

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 9 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 6 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 6 human up

A Gene Set from LINCS

GSE229973 cisplatin 3 v 6 human dn

A Gene Set from LINCS

GTEx Testis 20-29 vs 60-69 Down

A Gene Set from GTEx

GSE119978 GSE180930 cisplatin 0 v 5 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.